Maintenance Of Healing Duodenal Ulcer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for maintenance of healing duodenal ulcer. 7 active patents protecting 2 drugs from 1+ originators. First major cliff: 2036. Daily refresh.

2
Approved drugs
7
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Maintenance Of Healing Duodenal Ulcer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Yamanouchi/Merck) 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating maintenance of healing duodenal ulcer. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
26
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pepcid
famotidine
 Generic (originally Yamanouchi/Merck) 5 73 — 2026-07-18
Prevacid
lansoprazole
 Generic (originally Takeda) 2 49 — 2036-04-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8067451 Pepcid method of use 85 2026-07-18
8501228 Pepcid method of use 85 2026-07-18
8318202 Pepcid formulation 65 2026-07-18
8449910 Pepcid formulation 65 2026-07-18
8309127 Pepcid formulation 65 2026-07-18
11986554 Prevacid formulation 55 2036-04-21
11077055 Prevacid formulation 42 2036-04-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11077055 Prevacid formulation 42 2036-04-21
11986554 Prevacid formulation 55 2036-04-21
8318202 Pepcid formulation 65 2026-07-18
8449910 Pepcid formulation 65 2026-07-18
8309127 Pepcid formulation 65 2026-07-18
8067451 Pepcid method of use 85 2026-07-18
8501228 Pepcid method of use 85 2026-07-18

Related